Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Oncoinvent ASA's Debt-to-EBITDA or its related term are showing as below:
CHIX:ONCINo'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.06 Med: -0.01 Max: 0
Current: -0.03
CHIX:ONCINo's Debt-to-EBITDA is ranked worse than 100% of 302
companies
in the Biotechnology industry
Industry Median: 1.29
vs CHIX:ONCINo: -0.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Oncoinvent ASA Debt-to-EBITDA Related Terms
Oncoinvent ASA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Oncoinvent ASA (CHIX:ONCINO) has a Debt-to-EBITDA of -0.02 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Oncoinvent ASA. According to the industry distribution chart, Oncoinvent ASA ranks #999999 out of 302 companies in the Biotechnology industry.
Is Oncoinvent ASA's Debt-to-EBITDA too high?
Oncoinvent ASA's current Debt-to-EBITDA is -0.02. Based on the distribution chart, Oncoinvent ASA ranks #999999 out of 302 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #999999 out of 302 companies for Debt-to-EBITDA. This places Oncoinvent ASA in the lower half of its industry. The industry median Debt-to-EBITDA is 1.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.29, based on 302 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Oncoinvent ASA. For the Biotechnology industry, the median Debt-to-EBITDA is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current Debt-to-EBITDA is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Debt-to-EBITDA of -0.02. The stock's GF Value™ is kr11,054.88, compared to a current price of kr1,039.91 — trading 90.6% below its estimated fair value. The current Debt-to-EBITDA is -0.02. Oncoinvent ASA's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Debt-to-EBITDA is -0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 90.6% below its estimated GF Value™ of kr11,054.88.
Key valuation signals for CHIX:ONCINO:
Debt-to-EBITDA: -0.02
GF Value™: kr11,054.88 vs. price of kr1,039.91 (90.6% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
42GF Score
Get the complete analysis for CHIX:ONCINO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
